Nanostring Technologies, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$557Kgeneral payments (2019-2025)
$0.00research payments (2019-2025)
16clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Philip Bernard | Salt Lake City, UT | Anatomic Pathology & Clinical Pathology | $267,242.66 |
| Matthew Ellis | Houston, TX | Medical Oncology | $267,242.66 |
| Douglas Kingma | Franklin, TN | Hematology (Pathology) | $16,878.16 |
| Francisco Esteva | New York, NY | Medical Oncology | $3,185.90 |
| Faithlore Gardner | Cape Coral, FL | Medical Oncology | $1,588.85 |
| Eleni Andreopoulou | Houston, TX | Hematology & Oncology | $500.00 |
| Lowell Hart | Fort Myers, FL | Medical Oncology | $135.02 |
| Stefan Gluck | Miami, FL | Hematology & Oncology | $117.27 |
| James Reeves | Fort Myers, FL | Medical Oncology | $115.77 |
| Michael Mccleod | Fort Myers, FL | Medical Oncology | $88.55 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.